Fate Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bahram Valamehr
- Full Time Employees
- 161
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12278 Scripps Summit Drive San Diego CA United States of America 92131
- IPO Date
- Oct 1, 2013
- CIK
- 0001434316
- Website
- fatetherapeutics.com
- Similar Companies
- Business
- Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that develops off-the-shelf, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, including multiplexed-engineered T-cell and natural killer (NK) cell product candidates incorporating novel synthetic controls of cell function for the treatment of cancer and autoimmune diseases; its pipeline features FT819 (CD19 CAR T-cell with FDA RMAT designation in systemic lupus erythematosus), FT522 (CD19/CD20 CAR NK cell), FT839 (next-generation CD19/CD38/CD20 CAR T-cell), FT836 (next-generation multi-antigen CAR T-cell targeting MICA/B/EGFR/HER2 for solid/hematologic malignancies and CD19/CD38/BCMA/GPRC5D for hematologic malignancies), and FT825 (HER2/EGFR CAR NK cell), among others in Phase 1 for indications such as systemic lupus erythematosus, systemic sclerosis, ANCA-associated vasculitis, idiopathic inflammatory myopathies, and solid tumors. Founded in 2007 and headquartered in San Diego, California, the company conducts research, development, clinical operations, and cGMP manufacturing from its facilities there, with operations focused on the United States and recent expansion of clinical trial sites to the EU and UK. Latest developments include FDA IND allowance and Phase 1 initiation for FT836 in solid tumors, MHRA and EMA authorization to open ex-US sites for FT819 autoimmune trials, promising Phase 1 data for FT819 demonstrating durable SLEDAI-2K score reductions with no dose-limiting toxicities or graft-versus-host disease, extension of its partnership with Ono Pharmaceutical, plans for a registrational study of FT819 in moderate-to-severe SLE and lupus nephritis in 2026 under RMAT discussions with the FDA, and a cash runway extended through fiscal 2027 supported by $249 million in cash, equivalents, and investments as of Q2 2025.
Company News
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
The $13 Million Company Teaching the Immune System to Hunt Cancer
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases